Federal Court Decision on Scraping Increases GDPR-related Litigation Risks
21 November 2024
BICO has reached an agreement to sell Nanoscribe to LAB14 GmbH. BICO is a laboratory automation partner and provider of selected workflows to the pharmaceutical and biotechnology industries. With 46,000+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories. Operating through three business areas – Lab Automation, Life Science Solutions, and Bioprinting – BICO strives towards the vision to enable and automate the life science lab of the future. BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. Nanoscribe is a high-precision 3D printing technology company, specializing in two photon polymerization (2PP).
Hengeler Mueller team for BICO
M&A: Clemens Höhn (partner, lead, Berlin), Christoph Roth (senior associate, Munich), Moritz Evertz (senior associate, Düsseldorf), Felix Schwalm (associate, Berlin),
IP/IT: Matthias Rothkopf (counsel), Johannes Jäkle (associate, both Düsseldorf),
Public law/FDI: Jan D. Bonhage (partner), Nikolaus Wallraf (associate, both Berlin),
Antitrust: Christian Dankerl (counsel, Brüssel),
Tax: Markus Ernst (partner), Tim Würstlin (senior associate), Florian Lenhart (associate, all Munich),
Employment: Sonnhild Draack (counsel, Frankfurt).
